Prognosis
J&J’s Covid Vaccine Remains Paused as CDC Advisers Seek Data
- Vaccine advisory committee doesn’t make further recommendation
- Pause that had been seen as lasting days may persist for weeks
This article is for subscribers only.
U.S. public health advisers concluded a meeting on Johnson & Johnson’s Covid-19 vaccine without a vote, effectively extending a pause on its use while they seek more data on a rare clotting side effect.
After scrutinizing evidence related to the blood clots during an hours-long emergency meeting Wednesday, advisers to the U.S. Centers for Disease Control and Prevention said they lacked adequate information to make recommendations on how to respond to reports of the rare blood clots. The CDC’s Advisory Committee on Immunization Practices didn’t give a precise date for when they’ll reconvene to reconsider the vaccine.